Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech's primary liver cancer drug ThermoDox should produce pivotal Phase III data in the next 12 to 14 months.
You may also be interested in...
Financings Of The Fortnight Ponders A Post-Euro Financing Environment
Plus news on recent financings by TopiVert, Dendreon, Inhibitex and Celsion.
Celsion Initiates First International Licensing Deal With Japan’s Yakult For Liver Cancer Drug ThermoDox
TOKYO -Yakult Honsha Co. of Tokyo and Celsion of Columbia, Md., announced a licensing agreement for Celsion's liver cancer drug ThermoDox, marking Celsion's first international licensing deal
Celsion Could File ThermoDox Doxorubicin Delivery System For Liver Cancer By 2010
Company’s proprietary heat-sensitive liposome could provide drug delivery for several cancer types, CEO Tardugno tells “The Pink Sheet” DAILY.